ANVS Stock Analysis: Buy, Sell, or Hold?
ANVS - Annovis Bio, Inc.
$2.28
0.02 (0.88%)
▲
5d:
+14.0%
30d:
+40.74%
90d:
-8.43%
BUY
MODERATE Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: May 12, 2026
1d
Smart Money Distribution
ANVS is up 20.6% this week, but smart money is buying puts. Top strike: $2.5 2026-06-18 with 12 OI. Put ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When ANVS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ANVS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ANVS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ANVS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ANVS is currently trading at $2.28, which is considered extended relative to its 30-day fair value range of $1.73 to $2.18.
Technical Outlook: Technically, ANVS is in a strong downtrend. Immediate support is located at $1.75, while resistance sits at $2.44.
Market Sentiment: ANVS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.50 (+448.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ANVS is in a strong downtrend. Immediate support is located at $1.75, while resistance sits at $2.44.
Market Sentiment: ANVS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.50 (+448.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.73 -
$2.18
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 448.2% below Wall St target ($12.50)
Trading Range Analysis
30-Day Trading Range
$1.73 -
$2.18
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.75
Resistance Level
$2.44
Current Trend
Strong Downtrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.68
Wall Street Target
$12.50
(+448.2%)
Share & Embed Analysis
Last updated: May 10, 2026 3:20 PM ET
Data refreshes hourly during market hours. Next update: 4:20 PM
Data refreshes hourly during market hours. Next update: 4:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANVS showing a specific setup today?
Insider Activity (6 Months)
5
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Michael B Hoffman
BUY
713800 shares
2026-04-02
Michael B Hoffman
BUY
45000 shares
2025-12-08
Michael B Hoffman
BUY
39200 shares
2025-11-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 52 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$23 | 55 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$208 | 46 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 65 BUY |
